The House Oversight Committee kept pressure on drug middlemen at a hearing today that focused on a new committee report that criticizes industry practices.
Pharmacy benefit managers steer patients to PBM-owned pharmacies while underpaying competing pharmacies, according to the report, which highlights concerns that lawmakers have been pounding for years. The committee found evidence of PBMs sharing patient information among affiliated companies for the specific and anticompetitive purpose of steering patients to pharmacies a PBM owns.
The hearing keeps attention on PBM reforms as Congress nears the period between elections in November and when newly elected officials take office the following January. That lame duck period might be an opportune time for Congress to pass a health care legislative package that includes PBM reforms, though it’s difficult to predict what will happen following the elections.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect